CEF14, EBV Rta Protein 28-37

CEF14, EBV Rta Protein 28-37 is a synthetic peptide corresponding to amino acid residues 28 to 37 of the Epstein-Barr virus (EBV) Rta protein. As a defined peptide fragment, it represents a specific epitope derived from a key EBV transcriptional activator involved in viral lytic cycle regulation. CEF14 is widely utilized in immunological research due to its well-characterized sequence and its relevance in the study of antigen-specific T cell responses. The peptide's precise composition and immunogenic profile make it a valuable reagent for dissecting cellular immune mechanisms associated with EBV infection and broader viral immunology.

Immunological assay development: CEF14 is frequently employed as a reference antigen in the development and validation of T cell-based immunoassays. Its defined sequence enables researchers to assess the sensitivity and specificity of assays such as ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of peptide-specific CD8+ T cells. By serving as a positive control or test antigen, the peptide facilitates the optimization and benchmarking of immune monitoring platforms, particularly in studies of EBV-specific cellular immunity.

Epitope mapping and antigen specificity studies: The peptide is instrumental in mapping T cell epitopes recognized by human leukocyte antigen (HLA)-restricted cytotoxic T lymphocytes. Its use allows for the precise delineation of immune recognition sites within the Rta protein, supporting investigations into antigen processing, presentation, and the determinants of T cell specificity. Such studies are critical for elucidating the mechanisms of immune surveillance and viral escape in the context of EBV infection.

Vaccine research and immunogenicity assessment: CEF14 provides a model epitope for evaluating the immunogenic potential of candidate vaccine formulations targeting EBV or related herpesviruses. By incorporating the peptide into ex vivo or in vitro stimulation protocols, researchers can measure T cell activation and cytokine production, thereby gauging the efficacy of immunization strategies in eliciting robust cellular responses. This application underpins the rational design and preclinical evaluation of peptide-based vaccine candidates.

Functional T cell characterization: The peptide is utilized to stimulate peripheral blood mononuclear cells (PBMCs) or isolated T cell populations in functional assays, enabling detailed analysis of effector functions such as cytotoxicity, proliferation, and cytokine secretion. These experiments provide insights into the quality and breadth of antiviral T cell responses, supporting studies on immune competence, memory formation, and the impact of viral antigens on host immunity.

Quality control and standardization of peptide reagents: In addition to its direct research applications, CEF14 serves as a benchmark peptide for quality assurance in peptide synthesis, handling, and storage. Its well-defined sequence and immunological activity make it suitable for validating peptide integrity and performance in laboratory workflows. This role contributes to the reproducibility and reliability of experimental results in immunological and virological research settings.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

5. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines